A carregar...
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
BACKGROUND: There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. METHODS: Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 1...
Na minha lista:
Publicado no: | PLoS One |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Public Library of Science
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4880338/ https://ncbi.nlm.nih.gov/pubmed/27224517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0156221 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|